You searched for Gout - Page 60 of 96

Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…
Abstract Number: 151 • 2012 ACR/ARHP Annual Meeting
Management of Gout Attacks in the Community
Tuhina Neogi¹, Clara Chen², Christine E. Chaisson², David J. Hunter³, Hyon Choi⁴ and Yuqing Zhang⁵, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: We previously examined management of gout attacks in the community in 2003-4. Since then, new agents have become available and gout publications have increased,…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 154 • 2012 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods
Gabriel S. Breuer¹, Naama Bogot² and Gideon Nesher³, ¹Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Radiology, Shaare Zedek Medical Center p o box 3235 Jerusalem, Israel, Israel, ³Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel
Background/Purpose: Dual-energy computed tomography (DECT) is a sensitive method for identifying uric acid deposits in joints and periarticular soft tissues in patients suspected of having…
Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…
Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…
Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Puja Khanna¹, Veronica Berrocal², Tonya Hays³, Daniel J. Clauw⁴ and David A. Williams⁵, ¹Division of Rheumatology/Dept. of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Survey Research Center, UCLA, Los Angeles, CA, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…
Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…
Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Filipi M. Mello¹, Rafael B. Tomita², Ricardo Fuller³, Marco Antonio G. P. Filho², Thiago B. M. Barros⁴, Leandro L. do Prado², Kristopherson L. Augusto² and Claudia Goldenstein-Schainberg⁵, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Rheumatology Division - University of São Paulo, São Paulo, Brazil, ³Reumatologia, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Rheumatology Division - University of São Paulo, São Paulo, Brazil
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…
Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Melea Ward¹, Anthony M. Louder², Keith A. Szymanski³ and Leonardo Tamariz⁴, ¹Competitive Health Analytics, Louisville, KY, ²Competitive Health Analytics, Inc., Louisville, KY, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL, ⁴University of Miami, Miami, FL
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…
Abstract Number: 164 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Gout in a Large Tertiary Hospital and the Impact of in-Hospital Attacks of Acute Gout On Patient Outcomes and Health Resource Utilisation – a Nested Case-Control Study
John HY Moi¹, Mark Tacey², Carol Roberts³, Caroline Brand², Alexandra Gorelik³ and Sharon Van Doornum², ¹Department of Rheumatology, Department of Medicine (RMH), The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia, ²Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ³Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Acute gout can develop in hospitalised patients either as a new event or as a recurrence of established disease. To date there have been…
Abstract Number: 165 • 2012 ACR/ARHP Annual Meeting
Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study
Daria B. Crittenden¹, Cilian J. White¹, Michael DeBerardine¹, Grace Kim², Binita Shah³, Jessica C. Kimmel¹, Rima D. Patel¹, Steven P. Sedlis³, Jeffrey D. Greenberg⁴, Craig T. Tenner⁵, Bruce N. Cronstein¹ and Michael H. Pillinger¹, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Atherosclerosis is an inflammatory process, but to date no anti-inflammatory agent has definitively been shown to alter cardiovascular (CV) risk. Colchicine is an anti-inflammatory…
Abstract Number: 166 • 2012 ACR/ARHP Annual Meeting
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function
Michael DeBerardine¹, Mark C. Fisher², Robert T. Keenan³, Michael H. Pillinger⁴ and Daria B. Crittenden⁴, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Duke University, Durham, NC, ⁴Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Patients with chronic kidney disease (CKD) may be at increased risk for allopurinol (ALLO) hypersensitivity, possibly because impaired renal excretion causes accumulation of the…
Abstract Number: 134 • 2012 ACR/ARHP Annual Meeting
Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen! A Population Based Study
Adlene Jebakumar¹, Cynthia S. Crowson², P. Deepak Udayakumar¹ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Even though there are a few cases in the literature reporting co-existence of gout and rheumatoid arthritis (RA), it has been a long time…
Abstract Number: 136 • 2012 ACR/ARHP Annual Meeting
A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria
Rebecca Prowse¹, Nicola Dalbeth², H. R. Schumacher³, Tuhina Neogi⁴, Tim L. Jansen⁵, Jaap Fransen⁶ and William Taylor¹, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Boston University School of Medicine, Boston, MA, ⁵Rheumatology, St Radboud University Nijmegen Medical Centre, Netherlands, ⁶Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
A Delphi Exercise to Identify Characteristic Features of Gout - a Study of Opinions from Patients and Physicians to Inform New Classification CriteriaBackground/Purpose: Updated classification…

Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study

Management of Gout Attacks in the Community

Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)

Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods

Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study

Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10

Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study

Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout

Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients

Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout

The Prevalence of Gout in a Large Tertiary Hospital and the Impact of in-Hospital Attacks of Acute Gout On Patient Outcomes and Health Resource Utilisation – a Nested Case-Control Study

Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study

Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function

Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen! A Population Based Study

A Delphi Exercise to Identify Characteristic Features of Gout – A Study of Opinions From Patients and Physicians to Inform New Classification Criteria

Simple Search Results